Prevention of SARS-CoV-2 infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine

Wageningen University

Project: EU research project

2 Article
1 Comment/Letter to the editor

2 results

Filter

2021
Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
Fougeroux, C., Goksøyr, L., Idorn, M., Soroka, V., Myeni, S. K., Dagil, R., Janitzek, C. M., Søgaard, M., Aves, K. L., Horsted, E. W., Erdoğan, S. M., Gustavsson, T., Dorosz, J., Clemmensen, S., Fredsgaard, L., Thrane, S., Vidal-Calvo, E. E., Khalifé, P., Hulen, T. M., Choudhary, S., & 27 othersTheisen, M., Singh, S. K., Garcia-Senosiain, A., Van Oosten, L., Pijlman, G., Hierzberger, B., Domeyer, T., Nalewajek, B. W., Strøbæk, A., Skrzypczak, M., Andersson, L. F., Buus, S., Buus, A. S., Christensen, J. P., Dalebout, T. J., Iversen, K., Harritshøj, L. H., Mordmüller, B., Ullum, H., Reinert, L. S., de Jongh, W. A., Kikkert, M., Paludan, S. R., Theander, T. G., Nielsen, M. A., Salanti, A. & Sander, A. F., 12 Jan 2021, In: Nature Communications. 12, 1, 324.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
86 Citations (Scopus)
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants
van Oosten, L., Altenburg, J. J., Fougeroux, C., Geertsema, C., van den End, E. J., Evers, W. A. C., Westphal, A. H., Lindhoud, S., van den Berg, W. A. M., Swarts, D. C., Deurhof, L., Suhrbier, A., Le, T. T., Torres Morales, S., Myeni, S. K., Kikkert, M., Sander, A. F., de Jongh, W. A., Dagil, R., Nielsen, M. A., & 9 othersSalanti, A., Søgaard, M., Keijzer, T. M. P., Weijers, D., Eppink, M. H. M., Wijffels, R. H., van Oers, M. M., Martens, D. E. & Pijlman, G. P., 26 Oct 2021, In: mBio. 12, 5, e01813-21.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
27 Citations (Scopus)

Prevention of SARS-CoV-2 infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine

Research output

Search results

Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants